Zacks.com on MSN6d
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma StudyShares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...
NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...
Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage study of its investigational candidate, NUC-7738, in combination with ...
As of 09:30 CEST. Market open. On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's ...
On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda ...
Fazio reported being an invited speaker for Novartis and Ipsen; serving on advisory boards for Novartis, Ipsen, MSD, and Merck; serving as a principal investigator of trials for 4Sc, Astellas, BeiGene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback